449 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Purchased by National Wealth Management Group LLC

National Wealth Management Group LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 449 shares of the medical research company’s stock, valued at approximately $238,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Raleigh Capital Management Inc. raised its stake in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares during the period. Cedar Mountain Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after buying an additional 46 shares during the last quarter. Financial Connections Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $53,000. Operose Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 250.0% during the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after purchasing an additional 75 shares during the last quarter. Finally, Valley National Advisers Inc. boosted its holdings in Thermo Fisher Scientific by 40.5% in the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after purchasing an additional 32 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last quarter. 0.32% of the stock is currently owned by insiders.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Finally, HSBC upped their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Stock Up 4.8 %

NYSE:TMO traded up $26.30 on Tuesday, hitting $574.68. 1,409,556 shares of the company’s stock traded hands, compared to its average volume of 1,546,754. The firm has a 50-day moving average price of $571.30 and a 200-day moving average price of $528.18. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company has a market cap of $219.36 billion, a PE ratio of 35.49, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the business earned $5.40 EPS. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.